抗體相關的各種聯盟契約 - 契約條件、協定內容 (2014~2019年):資本交易趨勢、企業、財務狀況
市場調查報告書
商品編碼
234470

抗體相關的各種聯盟契約 - 契約條件、協定內容 (2014~2019年):資本交易趨勢、企業、財務狀況

Antibody Collaboration and Licensing Deals 2016-2023

出版日期: | 出版商: Current Partnering | 英文 950+ Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告提供抗體相關的各種資本交易/事業聯盟的契約締結相關分析,近幾年的各種契約的締結趨勢,及大規模契約及大醫藥品經營者的契約概要,各契約類型/各臨床實驗階段/各技術/各治療內容的契約一覽等資訊彙整,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 抗體相關的各種交易趨勢

  • 簡介
  • 近幾年的抗體相關的事業聯盟數量
  • 最活躍的,抗體相關的交易主體
  • 抗體相關的事業聯盟:各交易類型
  • 抗體相關的事業聯盟:各治療領域
  • 抗體相關的事業聯盟:交易條件
    • 交易總額 (headline values)
    • 預付款金
    • 階段性付款
    • 權利金費率

第3章 抗體相關的主要交易

  • 簡介
  • 代表性資本交易 - 交易金額

第4章 抗體相關的最活躍的交易主體

  • 簡介
  • 抗體相關的最活躍的交易主體
  • 最活躍的交易主體:企業簡介

第5章 抗體相關的契約締結的一覽

  • 簡介
  • 簽下的合約一覽 (名錄)

第6章 抗體相關的交易趨勢:各技術種類

第7章 抗體相關的資源中心

  • 抗體相關的聯網數據庫
  • 抗體相關的活動/會議
  • 抗體相關的參考文獻

附錄

  • 附錄 (1) - 抗體相關的資本交易:各企業 (ABC順序)
  • 附錄 (2) - 抗體相關的資本交易:各臨床實驗階段
    • 藥物研發
    • 前臨床
    • 第一階段
    • 第二階段
    • 第三階段
    • 申請登記
    • 已上市
    • 劑型
  • 附錄 (3) - 抗體相關的資本交易:各交易類型
    • 資產購買
    • 權利轉讓
    • 大醫藥品企業的對外授權
    • 共同開發
    • 共同研究開發 (R&D)
    • 共同行銷
    • 共同促銷
    • CRADA (共同研究開發契約)
    • 交叉授權
    • 開發
    • 流通
    • 股票購買
    • 評估
    • 轉讓
    • 合資企業 (合資企業)
    • 授權
    • 貸款
    • 製造
    • 行銷
    • 材料轉移
    • 選擇
    • 推銷
    • 研究
    • 和解調停
    • 衍生公司
    • 再授權
    • 供給
    • 技術轉移
    • 契約解除
  • 附錄 (4) - 抗體相關的資本交易:各治療領域
    • 心血管
    • 中樞神經系統
    • 牙科
    • 皮膚科
    • 消化器官
    • 血液
    • 住院治療
    • 免疫
    • 感染疾病
    • 代謝
    • 肌肉骨骼系統疾病
    • 產科
    • 腫瘤 (癌症)
    • 眼科
    • 罕見疾病
    • 小兒科
    • 精神科
    • 呼吸系統
  • 附錄 (5) - 資本交易的種類:定義

關於Wildwood Ventures

簡介目錄
Product Code: CP2113

Description

Antibody Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the antibody deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of antibody deals from 2016 to 2023.

The report provides a detailed understanding and analysis of how and why companies enter antibody deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1812 antibody deals announced since 2016 including financial terms where available including links to online deal records of actual antibody partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of antibody dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in antibody dealmaking since 2016.

Chapter 3 provides an overview of the leading antibody deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibody dealmaking with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of antibody deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific antibody technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in antibody deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse antibody collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, deal type and therapy area
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Report scope

  • Antibody Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of antibody trends and structure of deals entered into by leading biopharma companies worldwide.

Antibody Collaboration and Licensing Deals includes:

  • Trends in antibody dealmaking in the biopharma industry
  • Directory of antibody deal records covering pharmaceutical and biotechnology
  • The leading antibody deals by value
  • Most active antibody licensing dealmakers
  • Antibody Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

Antibody Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse antibody collaboration and licensing deals
  • Benchmark analysis - identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, deal type and therapy area
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in antibody dealmaking

  • 2.1. Introduction
  • 2.2. Antibody deals over the years
  • 2.3. Most active antibody dealmakers
  • 2.4. Antibody deals by deal type
  • 2.5. Antibody deals by therapy area
  • 2.6. Antibody deals by industry sector
  • 2.7. Deal terms for antibody deals
    • 2.7.1 Antibody deals headline values
    • 2.7.2 Antibody deal upfront payments
    • 2.7.3 Antibody deal milestone payments
    • 2.7.4 Antibody royalty rates

Chapter 3 - Leading antibody deals

  • 3.1. Introduction
  • 3.2. Top antibody deals by value

Chapter 4 - Most active antibody dealmakers

  • 4.1. Introduction
  • 4.2. Most active antibody dealmakers
  • 4.3. Most active antibody deals company profiles

Chapter 5 - Antibody contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Antibody contracts dealmaking directory

Chapter 6 - Antibody dealmaking by technology type

  • Deal directory
  • Deal directory - Antibody deals by company A-Z
  • Deal directory - Antibody deals by deal type
  • Deal directory - Antibody deals by therapy area
  • Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Antibody deals since 2016
  • Figure 2: Active antibody dealmaking activity - 2016 - 2023
  • Figure 3: Antibody deals by deal type since 2016
  • Figure 4: Antibody deals by therapy area since 2016
  • Figure 5: Antibody deals by industry sector since 2016
  • Figure 6: Antibody deals with a headline value
  • Figure 7: Antibody deals with an upfront value
  • Figure 8: Antibody deals with a milestone value
  • Figure 9: Antibody deals with a royalty rate value
  • Figure 10: Top antibody deals by value since 2016
  • Figure 11: Most active antibody dealmakers 2016 - 2023
  • Figure 12: Antibody deals by technology type since 2016